Sildenafil Citrate Tablet
Product Images NDC 75834-241

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Sildenafil Citrate (NDC 75834-241). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nivagen Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Sildenafil-citrate-100-mg-1000s (Sildenafil Citrate 100 mg 1000s)

Sildenafil Tablets, USP 100 mg oral tablets label by Nivagen Pharmaceuticals, Inc. The label shows packaging for a supply of 1000 tablets. It includes storage instructions at 25°C (77°F) with specific temperature excursions allowed. The label features the Nivagen logo, NDC 75834-241-00, and manufacturing details for Nivagen Pharmaceuticals in Sacramento, California, and Umedica Laboratories in India.*

FDA Label Image

Sildenafil-citrate-100-mg-30s (Sildenafil Citrate 100 mg 30s)

Label for Sildenafil Citrate Tablets, USP, 100 mg, oral tablet by Nivagen Pharmaceuticals, Inc. The label indicates the drug contains 100 mg sildenafil citrate per tablet, in a package of 30 tablets. Storage instructions specify 25°C (77°F) excursions permitted to 15-30°C (59-86°F). The label includes the NDC 75834-241-30 and manufacturer details, including Umedica Laboratories Pvt. Ltd. in India.*

FDA Label Image

Sildenafil Citrate 25 mg 90s

Sildenafil Tablets, USP 25 mg oral tablets by Nivagen Pharmaceuticals, Inc. The label shows a package containing 90 tablets with dosage strength of 25 mg. Storage instructions, manufacturer details for Nivagen Pharmaceuticals in Sacramento, CA and Umedica Laboratories Pvt. Ltd. in India, and a barcode are visible. The package is marked Rx only.*

FDA Label Image

Sildenafil-citrate-50-mg-1000s.jpg (Sildenafil Citrate 50 mg 1000s)

Label for Sildenafil Tablets, USP 50 mg by Nivagen Pharmaceuticals, Inc. The label states the product contains sildenafil citrate equivalent to 50 mg sildenafil per tablet. The package includes 1000 tablets and storage instructions specify 25°C with excursions allowed between 15-30°C. The label shows manufacturer information for Nivagen Pharmaceuticals, Sacramento, CA, and Umedica Laboratories Pvt. Ltd., India. Barcode and prescription-only status are also visible.*

FDA Label Image

Sildenafil-citrate-30-mg-30s (Sildenafil Citrate 50 mg 30s)

Sildenafil Citrate 50 mg tablet label for oral use by Nivagen Pharmaceuticals, Inc. The label states it contains 30 tablets, is prescription only, and includes storage instructions and dosage directions referencing accompanying information. Manufactured by Umedica Laboratories Pvt. Ltd. in India, with contact details for the U.S. manufacturer.*

FDA Label Image

Sildenafil-citrate-figure-1 (Sildenafil Citrate Figure 1)

A line graph titled 'Mean Change from Baseline in Sitting Systolic Blood Pressure, Healthy Volunteers,' showing changes in systolic blood pressure (mmHg) over 24 hours post dose. The x-axis represents time in hours, and the y-axis shows systolic blood pressure changes. Two lines display data for Sildenafil 100 mg and Placebo groups.*

FDA Label Image

Sildenafil-citrate-figure-2 (Sildenafil Citrate Figure 2)

A line graph depicting mean standing systolic blood pressure change from baseline over time postdose (0 to 8 hours). Two data series are shown: Doxazosin + Placebo and Doxazosin + Sildenafil 25 mg, with changes measured in mmHg on the vertical axis and time in hours on the horizontal axis.*

FDA Label Image

Sildenafil-citrate-figure-3 (Sildenafil Citrate Figure 3)

A line graph showing the mean change in standing systolic blood pressure (mmHg) over time (hours) post-dose. Two data series are plotted: Doxazosin + Placebo and Doxazosin + Sildenafil 50 mg. The graph depicts changes from baseline, with the vertical axis representing pressure change and the horizontal axis representing time up to 8 hours.*

FDA Label Image

Sildenafil-citrate-figure-4 (Sildenafil Citrate Figure 4)

A line graph depicting mean standing systolic blood pressure change from baseline over an 8-hour period. Two data series compare the effect of doxazosin combined with sildenafil 100 mg versus doxazosin with placebo, showing blood pressure change in mmHg on the y-axis against time after dosing in hours on the x-axis.*

FDA Label Image

Sildenafil-citrate-figure-5 (Sildenafil Citrate Figure 5)

A line graph titled 'Mean Sildenafil Plasma Concentrations in Healthy Male Volunteers' showing plasma concentration (ng/mL) on the vertical axis versus time post dose (hours) on the horizontal axis. The curve depicts plasma concentration rising sharply to a peak around 1 hour after dosing, then gradually declining over 24 hours, indicating the pharmacokinetic profile of sildenafil following oral administration.*

FDA Label Image

Sildenafil-citrate-figure-6 (Sildenafil Citrate Figure 6)

Two bar charts comparing the effect of sildenafil citrate and placebo on the maintenance of erection by baseline score. The vertical axis shows the percentage of patients at endpoint, and the horizontal axis displays baseline scores from 0 to 5. Different shades represent scores 0 through 5 in the legend.*

FDA Label Image

Sildenafil-citrate-figure-7 (Sildenafil Citrate Figure 7)

A bar chart displaying the percentage of patients reporting improvement across different treatment groups. The x-axis lists placebo and Sildenafil citrate doses (25 mg, 50 mg, 100 mg) with corresponding sample sizes. The y-axis shows the percentage scale from 0 to 100%, highlighting increased improvement percentages with higher Sildenafil citrate doses compared to placebo.*

FDA Label Image

Sildenafil-citrate-strecture (Sildenafil Citrate Strecture)

Chemical structure of Sildenafil Citrate, showing the molecular arrangement including the pyrazolo-pyrimidinone core, sulfonyl group, and ethoxyphenyl side chain characteristic of this active ingredient.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.